Article citationsMore>>

Levitsky, J., Fiel, M.I., Norvell, J.P., Wang, E., Watt, K.D., Curry, M.P., Tewani, S., et al. (2012) Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology, 142, 1132-1139.
http://dx.doi.org/10.1053/j.gastro.2012.01.030

has been cited by the following article:

• TITLE: Post-transplant plasma cell hepatitis in a liver transplant patient treated with pegylated interferon plus ribavirin

  AUTHORS: Miguel Jiménez-Pérez, Francisco Javier Rando-Muñoz, Rocío González-Grande, Fernando González-Panizo Tamargo, Jesús de la Cruz Lombardo, Juan Miguel Rodrigo López, Román Manteca González

  KEYWORDS: Liver Transplantation; C Hepatitis Treatment; Plasmatic Cells; Allograft Rejection; Autoinmune Response

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.3 No.7, November 26, 2013

  ABSTRACT: The recurrence of hepatitis C after a liver transplant remains an important cause of graft loss and retransplant. Antiviral therapy with peginterferon plus ribavirin (PEG-INF/RBV) can achieve a sustained viral response and histological improvement in a high percentage of cases. However, this treatment is not exempt from important side effects or from the possibility of precipitating rejection, with the resulting graft loss. We report the case of a liver transplant patient who received treatment with PEG-INF/RBV and developed plasma cell hepatitis as the presenting form of rejection.